Eli Lilly’s Neutral Momentum: A Closer Look at Q3 2026 Performance

Eli Lilly’s Q3 2026 earnings reveal strong growth driven by its flagship products, but technical indicators suggest a neutral outlook. Here’s what investors should watch.

Eli Lilly’s third-quarter 2026 earnings report showcased a 39% year-over-year revenue increase, driven largely by the success of Mounjaro and Zepbound. However, despite these impressive numbers, technical indicators from Metalgo5’s November 2nd snapshot paint a neutral picture, with a hold strategy signal and stretched RSI levels. Here’s a breakdown of the company’s performance and what it means for investors.

Revenue Growth and Product Performance

Eli Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase compared to the same period last year. This growth was primarily fueled by Mounjaro and Zepbound, which collectively accounted for $16.1 billion in sales. Mounjaro, a GLP-1 receptor agonist for type 2 diabetes, saw a 65% increase in revenue, while Zepbound, its obesity treatment counterpart, grew by 49%. The company also raised its full-year revenue guidance to $91-92 billion, reflecting confidence in its product pipeline and market demand [1].

New product launches, such as Foundayo, an oral GLP-1 agonist for obesity, contributed $184 million in Q3 sales. While this fell short of analyst expectations, Foundayo’s uptake is expected to accelerate as it gains traction in international markets and secures additional regulatory approvals [2].

Regulatory and Pipeline Milestones

Lilly’s regulatory progress in Q3 was noteworthy, with FDA approvals for Mounjaro to reduce cardiovascular risk in type 2 diabetes, Onswik for type 2 diabetes, and Inluriyo in combination with Verzenio for advanced breast cancer. These approvals underscore the company’s ability to expand the indications for its existing products [1].

The pipeline also saw significant advancements, including positive Phase 3 results for retatrutide, which demonstrated superior efficacy compared to Novo Nordisk’s Ozempic in head-to-head trials. Additionally, Phase 2 results for EloraTZP, a combination therapy for obesity and type 2 diabetes, showed promising weight loss and glycemic control outcomes [3].

Technical Indicators and Market Sentiment

Despite strong fundamentals, Metalgo5’s technical analysis suggests a neutral outlook for Eli Lilly’s stock. The November 2nd snapshot highlights an RSI of 76.75, indicating overbought conditions, and a MACD of 55.72, which, while bullish, is tempered by a declining MACD signal line. The strategy signal remains a 'Hold,' with low confidence (48.1%) and an expired Darvas breakout setup. Volume metrics also fail to confirm bullish momentum, with a volume ratio of 0.7476 and no breakout activity [4].

These indicators suggest that while Eli Lilly’s long-term prospects remain strong, short-term momentum may be stalled. Investors should monitor upcoming catalysts, such as additional regulatory approvals and pipeline updates, for potential shifts in sentiment.

Challenges and Opportunities Ahead

Lilly’s recent acquisitions, including AtaiBeckley and Merida Biosciences, signal its commitment to expanding its portfolio in mental health and autoimmune diseases. However, these deals come with significant IPR&D charges, which impacted Q3 earnings. The company’s ability to integrate these acquisitions and deliver on their potential will be critical [5].

Another area to watch is the Medicare GLP-1 Bridge program, which has expanded access to Lilly’s obesity medicines for Medicare beneficiaries. While this program has driven initial uptake, its long-term impact remains uncertain as policymakers debate broader coverage options [6].